Cutaquig^® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products

Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig^® treatment offered a tolerable and safe alternative treatment for immunodeficient patients....

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sydney Brownlee, Crystal Allen, Mohammed F. Kana’an, D. William Cameron, Juthaporn Cowan
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2022-11-01
Ráidu:	Hematology Reports
Fáttát:	hypogammaglobulinemia immunoglobulin treatment subcutaneous immunoglobulin tolerability Cutaquig<sup>®</sup>
Liŋkkat:	https://www.mdpi.com/2038-8330/14/4/48
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!